DaVita Inc. (NYSE:DVA) Receives $157.00 Average Price Target from Analysts

DaVita Inc. (NYSE:DVA) has received a consensus rating of “Hold” from the five research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $159.00.

DVA has been the topic of several recent analyst reports. TD Cowen boosted their target price on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. UBS Group boosted their target price on shares of DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Truist Financial boosted their target price on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, Bank of America boosted their target price on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th.

Insider Transactions at DaVita

In other news, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total value of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares of the company’s stock, valued at $141,219,407.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the sale, the insider now directly owns 83,011 shares in the company, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 173,482 shares of company stock worth $27,387,069. 2.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

Large investors have recently added to or reduced their stakes in the business. Blue Trust Inc. increased its position in shares of DaVita by 58.6% in the 2nd quarter. Blue Trust Inc. now owns 211 shares of the company’s stock valued at $29,000 after purchasing an additional 78 shares during the last quarter. Newbridge Financial Services Group Inc. purchased a new stake in shares of DaVita in the 4th quarter valued at approximately $30,000. Family Firm Inc. purchased a new stake in shares of DaVita in the 2nd quarter valued at approximately $43,000. Versant Capital Management Inc increased its position in shares of DaVita by 90.6% in the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock valued at $45,000 after purchasing an additional 155 shares during the last quarter. Finally, Friedenthal Financial purchased a new stake in shares of DaVita in the 2nd quarter valued at approximately $48,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

DVA opened at $160.85 on Monday. The firm has a market capitalization of $14.11 billion, a PE ratio of 18.28, a PEG ratio of 0.91 and a beta of 0.87. DaVita has a twelve month low of $71.84 and a twelve month high of $166.04. The firm’s 50-day moving average price is $154.19 and its 200 day moving average price is $143.78. The company has a current ratio of 1.16, a quick ratio of 1.12 and a debt-to-equity ratio of 9.94.

DaVita (NYSE:DVA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.47 by $0.12. The firm had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.15 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. DaVita’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.08 earnings per share. As a group, sell-side analysts expect that DaVita will post 9.99 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.